Hochman David P forfeited 6,566 Orchestra BioMed Holdings shares across two transactions at $5.81 per share. The transactions leave him with 432,916 shares, giving investors a precise view of his remaining ownership position after the reported share forfeitures.
Key Highlights
- The two transactions were completed on September 10, 2026.
- Each transaction carried transaction code F, used for tax-related withholding.
- Hochman David P held 432,916 Orchestra BioMed Holdings shares after the transactions.
Hochman David P forfeited 6,566 shares of Orchestra BioMed Holdings (NASDAQ: OBIO), leaving a reported holding of 432,916 shares after the transactions. The forfeitures occurred across two transactions priced at $5.81 per share.
The transactions took place on September 10, 2026. The combined amount was 6,566 shares. Each share was recorded at $5.81 per share. Orchestra BioMed Holdings was identified in the transaction record.
Post-Transaction Ownership
Hochman David P owned 432,916 Orchestra BioMed Holdings shares after the two transactions. That post-transaction balance is the reported ownership figure following the 6,566-share forfeiture. The reported price for the affected shares was $5.81 per share.
FAQs
Q: What happened in Hochman David P’s Orchestra BioMed insider transaction?
A: Hochman David P forfeited 6,566 Orchestra BioMed Holdings shares across two transactions. Both transactions were recorded on September 10, 2026, at $5.81 per share.
Q: How many Orchestra BioMed shares did Hochman David P retain?
A: Hochman David P owned 432,916 Orchestra BioMed Holdings shares after the transactions. The balance reflects his reported ownership following the share forfeitures.
Q: What does transaction code F mean in this insider transaction?
A: In this transaction record, code F identifies the two transactions in which Hochman David P forfeited Orchestra BioMed Holdings shares. Together, they involved 6,566 shares.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.